CPT® Code 87467

1. Indications

Quantitative hepatitis B surface antigen (HBsAg) testing is indicated for patients who have a confirmed diagnosis of hepatitis B infection. The test is particularly useful in the following scenarios:

• Monitoring Treatment Response This test helps assess how well a patient is responding to antiviral therapy for chronic hepatitis B infection.
• Evaluating Relapse It is used to determine if there is a relapse in patients undergoing prolonged antiviral therapy.
• Guiding Treatment Decisions The results can inform decisions about whether to continue current treatment, switch to another antiviral medication, or discontinue treatment to avoid unnecessary side effects.

2. Procedure

The procedure for conducting quantitative hepatitis B surface antigen (HBsAg) testing involves several key steps:

• Sample Collection A blood sample is drawn from the patient, typically from a vein in the arm. This sample is essential for the subsequent testing process.
• Sample Preparation The collected blood is processed in the laboratory to separate the serum, which contains the HBsAg. This step is crucial for accurate measurement.
• Immunoassay Technique The serum is then subjected to an immunoassay technique, such as immunochemiluminometric assay (IMCA), to detect and quantify the presence of HBsAg. This technique utilizes specific antibodies that bind to the HBsAg, allowing for its measurement.
• Result Interpretation After the assay is completed, the results are analyzed to determine the concentration of HBsAg in the serum. These results are then reported to the healthcare provider for further evaluation.

3. Post-Procedure

After the quantitative hepatitis B surface antigen (HBsAg) testing procedure, patients may not require any specific post-procedure care. However, it is important for healthcare providers to discuss the results with the patient, as these results can significantly impact treatment decisions. Patients should be informed about the implications of their HBsAg levels, including the potential need for adjustments in their antiviral therapy. Additionally, healthcare providers may recommend follow-up testing, such as HBV DNA viral load measurements, to further assess the patient's condition and treatment response.